Nanodx Inc. is readying for a U.S. pivotal trial of its nanowire biosensor technology. The company’s flagship product is designed to detect and quantify biomarkers proteins from a small fluid specimen of blood or saliva in less than four minutes and was developed in partnership with Skywater Technology Inc. and IBM Research. The privately held company is focusing on two clinical indications: traumatic brain injury (TBI) and COVID-19.